Tumour Progression
Recent successes:
-
Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38.
Pearce L, Morgan L, Lin TT, Hewamana S, Matthews RJ, Deaglio S, Rowntree C, Fegan C, Pepper C, Brennan P, Haematologica , Volume 95 , 3 (March 2010) pp.514-517
Our objectives in this area are to:
- Elucidate the biological significance of CD38, the pathogenic importance of B-cell receptor signalling and NF-kB transcriptional regulation in Chronic Lymphocyte Leukaemia.
Dr Chris Pepper and Dr Paul Brennan, Haematology dept
- Investigate cytogenetic instability and clonal evolution in CLL.
Dr Duncan Baird and Dr Chris Pepper, Haematology dept
- Understand the cellular signalling pathways regulating cancer cells motility and invasion and the mechanisms of oncogene induced cellular senescence.
Dr Zaruhi Poghosyan, Pathology dept
- Extend in vitro models of preleukaemia/leukaemia to further elucidate the molecular basis of myloid neoplasia.
Dr Richard Darley and Dr Alex Tonks, Haematology dept, Target discovery and translation
- Investigate stem cells in relation to skin and other cancers.
Dr Girish Patel
- To determine the somatic germline pathways of tumour initiation and progression in MAP and attentuated-FAP cancer patients.
Prof Julian Sampson and Prof Jeremy Cheadle, Medical Genetics dept
- To study the pathway of TSC-associated renal tumourigenesis.
Prof Jeremy Cheadle, Medical Genetics dept
- The cancer cell cycle and routes to chromosomal instability.
Prof Paul Smith, Pathology dept
- Development of high kinetic assays for screening the action of therapeutic agents in cells and tissue.
Dr Rachel Errington, Pathology dept
- Capitalize further on the potential of the Human Gene Mutation Database to provide in silico highlights into the pathogenesis of human mutation.
Prof David Cooper, Medical Genetics dept, Human Gene Mutation Group
Publications
- Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C, Oscier DG, Stankovic T, Pepper C, Baird DM, Leukemia, Volume 26, 4 (April 2012) pp.826-830 - Expression of CD200 on AML blasts directly suppresses memory T-cell function.
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, Tonks A, Leukemia (March 2012) - Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3(+) regulatory T cells.
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, Tonks A, Leukemia (March 2012) - Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.
Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C, Clin Cancer Res, Volume 18, 3 (February 2012) pp.678-687 - Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study.
Sharma A, Gentry-Maharaj A, Burnell M, Fourkala EO, Campbell S, Amso N, Seif MW, Ryan A, Parmar M, Jacobs I, Menon U, UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) None, Bjog, Volume 119, 2 (January 2012) pp.207-219